Skip to main
  1. Stocks
  2. ANI Pharma
  3. Forecast
ANIP

ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharma (ANIP) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 25%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

ANI Pharmaceuticals is supported by a 3Q 2026 beat on both revenue and EPS, with sales of $290.8M and non-GAAP EPS of $2.70, driven by stronger Generics performance and lower SG&A and R&D spending. Although Cortrophin sales of $138.66M missed expectations and FY 2026 guidance was cut to $480M-$500M, management framed the shortfall as a conversion bottleneck rather than weaker demand, citing doubled new gout cases QoQ and a 67% QoQ increase in gout prescribers. The proposed Egetis Therapeutics acquisition, plus stronger Iluvien sales of $22.3M and a rare-disease strategy that deepens ANI’s portfolio, supports the view that the company can compound growth while shifting toward higher-value specialty assets.

Bears say

ANI Pharmaceuticals is facing a fragile outlook because its most important growth drivers remain exposed to unforeseen clinical, regulatory, manufacturing, or commercial setbacks or delays, particularly for Purified Cortrophin Gel and Iluvien. The company also has execution risk from continued challenges with the Alimera integration and uncertainty around its ability to complete attractive future deals, which could slow the expected contribution from its Rare Disease and Brands businesses. Meanwhile, worsening pricing and competitive pressures in the generics industry threaten the Generics and Other segment, increasing the risk that overall revenue and margin performance will remain under pressure.

ANI Pharma (ANIP) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 25% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.

ANI Pharma (ANIP) Analyst Forecast & Price Prediction

Get the latest ANI Pharma (ANIP) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ANI Pharma (ANIP)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ANI Pharma (ANIP) Forecast

Analysts have given ANI Pharma (ANIP) a Buy based on their latest research and market trends.

According to 4 analysts, ANI Pharma (ANIP) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ANI Pharma (ANIP)


ANI Pharma (ANIP) Analyst Forecast & Price Prediction

Get the latest ANI Pharma (ANIP) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ANI Pharma (ANIP)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ANIP stock data and trends